Evaluation of Different Treatment Regimens for Relapsed and Refractory NHL: Single Institute Experience

Journal of Cancer Therapy
doi 10.4236/jct.2019.108053
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Scientific Research Publishing, Inc.

Related search

Salvage Treatment for Refractory or Relapsed Acute Myeloid Leukemia: A 10-Year Single-Center Experience

Clinics
Medicine
2020English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Nelarabine Treatment in Adult Patients With Refractory/ Relapsed T-Cell Acute Lymphoblastic Leukaemia/Lymphoma: Experience of a Single Centre

Gematologiya i Transfuziologiya
Hematology
2019English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Treatment of Relapsed and Refractory T-Cell Lymphomas: First Pavlov State Medical University of Saint-Petersburg Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Refractory and Relapsed Hodgkin's Lymphoma: Facts and Perspectives

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy